Monocyte procoagulant activity in breast cancer.
Abnormalities of blood coagulation associated with neoplasia may be important in the pathogenesis of tumour spread. Most patients with advanced malignancy have evidence of activated coagulation, but the mechanisms underlying this are unclear. We have examined in vitro monocyte procoagulant activity and compared this to plasma levels of fibrinopeptide A, in 52 patients with clinically localised breast cancer. Patients with localised breast cancer and activated coagulation displayed a strong positive correlation between monocyte procoagulant activity and level of fibrinopeptide A(r = +0.86, p less than 0.001). No such relationship was demonstrated in a smaller number of patients with metastatic breast cancer. It is concluded that monocyte procoagulant activity plays an important role in coagulation activation in patients with localised breast cancer. The implications of this for adjuvant anticoagulant therapy in breast cancer are discussed.
Auger
M J
MJ
University Department of Haematology, Royal Liverpool Hospital, United Kingdom.
Mackie
M J
MJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001779:Blood Coagulation Factors / Q000378:metabolism*; D001943:Breast Neoplasms / Q000097:blood*; D005260:Female; D005344:Fibrinopeptide A / Q000032:analysis / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000502:physiology*; D009362:Neoplasm Metastasis
D001779:Blood Coagulation Factors; C045071:leukocyte procoagulant activity; D005344:Fibrinopeptide A